Lv2
120 积分 2024-10-28 加入
Lack of CD8 + T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
13天前
已完结
ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO
1个月前
已关闭
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Defining immune reset: achieving sustained remission in autoimmune diseases
1个月前
已完结
Preclinical evaluation of efficacy and cytokine release of bispecific T cell engagers in humanized NSG mice
2个月前
已关闭
Fifty years of monoclonals: the past, present and future of antibody therapeutics
2个月前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
3个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
3个月前
已完结
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
3个月前
已完结
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
3个月前
已完结
皖公网安备34019202002308
